Abstract
Matrix metalloproteinases (MMPs) have been implicated in the process of tumor invasion and metastasis formation. Thus, we determined the expression of MMPs in various primary and metastatic spinal tumors in order to assess the role of these enzymes in spinal invasion. MMP expression was examined by immuno-histochemical localization, and quantitative evaluation of MMP protein content was determined by enzyme-linked immunosorbant assay (ELISA) and Western blotting. MMP enzyme activity was determined by gelatin zymography. Lung carcinomas and melanomas metastatic to the spine were shown to have higher levels of MMP-9 activity than those of breast, thyroid, renal metastases and primary spinal tumors. Immunohistochemical analysis revealed similar difference in expression of MMP-9 in tissue samples. When the tissue samples were subjected to gelatin zymography for examination of MMP-2 and MMP-9 activity and to ELISA and Western blotting for quantitative estimation of protein content, the most striking results were obtained for lung carcinomas and melanomas relative to the other tumors. Lung carcinomas and melanomas metastatic to the spine had considerably higher levels of MMP-9 activity than those of primary spinal tumor or breast, thyroid, and renal carcinoma metastases. Within the metastatic tumor category, neoplasms that are known to be associated with the shortest overall survival rates and most aggressive behavior, such as lung carcinomas and melanomas, had the highest levels of MMP-2 and MMP-9 activity compared to those less aggressive metastatic tumors such as breast, renal cell, and thyroid carcinomas. Our results suggest that MMPs may contribute to the metastases to the spinal column, and overexpression of these enzymes may correlate with enhanced invasive properties of both primary and metastatic spinal tumors.© Kluwer Academic Publishers 1998
Similar content being viewed by others
References
Sundaresan N, Galicich JH, Chu FC and Huvos AG, 1979, Spinal chordomas. J Neurosurg, 50, 312-19.
Black P, 1979, Spinal metastasis: current status and recommended guidelines for management. Neurosurgery, 5, 726-46.
Harrington KD, 1986, Metastatic disease of the spine. J Bone Joint Surg Am, 68, 1110-15.
Kostuik JP and Weinstein JN, 1991, Differential diagnosis and surgical treatment of metastastic spine tumors. In: Frymoyer JW, ed: The Adult Spine: Principles and Practice.New York: Raven Press, 861-88.
Cummings BJ, Esses S and Harwood AR, 1982, The treatment of chordomas. Cancer Treat Rev, 9, 299-311.
Rich TA, Schiller A, Suit HD and Mankin HJ, 1985, Clinical and pathologic review of 48 cases of chordoma. Cancer, 56, 182-7.
Komiya S, Inoue A, Nakashima M, et al.1986, Prognostic factors in giant cell tumor of bone. A modified histological grading system useful as a guide to prognosis. Arch Orthop Trauma Surg, 105, 67-72.
Nicholson GL, 1989, Metastastic cell interactions with endothelium, basement membrane and tissue. Curr Opin Cell Biol, 1, 1009-19.
Matrisian LM, 1992, The matrix degrading metalloproteinases. Bioessays, 14, 455-63.
Nagase H, Ogata Y, Suzuki K, et al.1991, Substrate specificities and activation mechanisms of matrix metalloproteinases. Biochem Soc Trans, 19, 715-18.
Stearns ME and Wang M, 1993, Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue. Cancer Res, 53, 878-83.
Pyke C, Ralfkiaer E, Tryggvason D and Dano K, 1993, Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol, 142, 359-65.
Monteagudo C, Merino MJ, San-Juan J, et al.1990, Immunohistochemical distribution of type IV collagenase in normal, benign and malignant breast tissue. Am J Pathol, 136, 585-92.
Pyke C, Ralfkiaer E, Huhtala P, et al.1992, Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situhybridization. Cancer Res, 52, 1336-41.
Koshikawa N, Yasumitsu H, Umeda M and Miyazaki K, 1992, Multiple secretion of matrix serine proteinases by human gastric carcinoma cell lines. Cancer Res, 52, 5046-53.
Schwartz GK, Wang H, Lampen N, et al,1994, Defining the invasive phenotype of proximal gastric cancer cells. Cancer, 73, 22-27.
Taniguchi S, Iwamura T and Katsuki T, 1992, Correlation between spontaneous metastatic potential and type I collagenolytic activity in a human pancreatic cancer cell line (SUIT-2) and sublines. Clin Exp Metastasis, 10, 259-66.
Zucker S, Lysik RM, Wieman J, et al.1985, Diversity of human pancreatic cancer cell proteinases: role of cell membrane metalloproteinases in collagenolysis and cytolysis. Cancer Res, 45, 6168-78.
Liotta LA, Steeg PS and Stetler-Stevenson WG, 1991, Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64, 327-36.
Schultz R, Silberman S, Persky G, et al.1988, Inhibition by human recombinant tissue inhibitor of metalloproteinases of human aminion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res, 48, 5539-45.
Nakajima M, Welch D, Belloni PN and Nicholson GL, 1987, Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Res, 47, 4869-76.
Liotta LA, Tryggvason K and Garbisa S, 1980, Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature, 284, 67-68.
Turpeenniemi-Hujanen T, Thorgeirsson UP, Hart IR, et al.1985, Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential. J Natl Cancer Inst, 75, 99-103.
Rao VH, Singh RK and Bridge JA, et al.1997, Regulation of MMP-9 (92 kDa type IV collagenase/gelatinase B) expression in stromal cells of human giant cell tumor of bone. Clin Exp Metastasis, 15, 400-9.
Rao VH, Bridge JA and Neff JR, et al.1995, Expression of 72-kDa and 92-kDa Type IV collagenases from human giant cell tumor of bone. Clin Exp Metastasis, 13, 420-6.
Sasaguri Y, Komiya S and Sugama K, et al.1992, Production of matrix metalloproteinases 2 and 3 (stromelysin) by stromal cells of giant cell tumor of bone. Am J Pathol, 141, 611-21.
Rao JS, Steck PA, Mohanam S, et al.1993, Elevated levels of Mr 92,000 type IV collagenase in human brain tumors. Cancer Res, 53, 2208-11.
Liotta LA and Stetler-Stevenson WG, 1991, Tumor invasion and metastasis: an imbalance of positive and negative regulators. Cancer Res, 51, 50543-95.
Ballin M, Gomez DE, Sinha CC and Thorgeirsson UP, 1988, RAS Oncogene mediated induction of a 92 Kda metalloproteinase; strong correlation with the malignant phenotype. Biochem Biophy Res Commun, 154, 832-8.
Stetler-Stevenson WG, 1990, Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev, 9, 289-303.
Testa JE, 1992, Loss of the metastatic phenotype by a human epidermoid carcinoma cell line, Hep-3, is accompanied by increased expression of tissue inhibitor of metalloproteinase 2. Cancer Res, 52, 5597-603.
Alvarez O, Carmichael D and DeClerck Y, 1990, Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J Natl Cancer Inst, 82, 589-95.
Welgus HG, Jeffrey JJ, Eisen AZ, et al.1985, Human skin fibroblast collagenase: interaction with substrate and inhibitor. Collagen Related Res, 5, 167-79.
Tsuchiya Y, Sato H and Endo Y, et al.1993, Tissue inhibitor of metalloproteinase 1 is a negative regulator of the metastatic ability of a human gastric cancer cell line, KKLS, in the chick embryo. Cancer Res, 53, 1397-1402.
DeClerck YA, Perez N, Shimada H, et al.1992, Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res, 52, 701-8.
Okada Y, Gonoji Y and Naka K, et al.1992, Matrix metalloproteinase 9 (92-KDa gelatinase/Type IV collagenase) from the HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. J Biol Chem, 267, 21712-19.
Okada Y, Naka K and Kawamura K, et al.1995, Localization of matrix metalloproteinase 9 (92-kilodalton gelatinase/type IV collagenase = gelatinase B) in osteoclasts: implications for bone resorption. Lab Invest, 72, 311-22.
Lang FF and Sawaya R, 1996, Surgical management of cerebral metastases. Neurosurg Clin N Am, 7, 459-84.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gokaslan, Z.L., Chintala, S.K., York, J.E. et al. Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumors. Clin Exp Metastasis 16, 721–728 (1998). https://doi.org/10.1023/A:1006580728338
Issue Date:
DOI: https://doi.org/10.1023/A:1006580728338